Herzuma Indications/Uses

Breast Cancer: Metastatic Breast Cancer (MBC): Herzuma is indicated for the treatment of patients with metastatic breast cancer who have tumors that overexpress HER2: a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; b) in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease; c) in combination with an aromatase inhibitor for the treatment of patients with hormone-receptor-positive metastatic breast cancer.
Early Breast Cancer (EBC): Herzuma is indicated for the treatment of patients with HER2-positive early breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable); following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel; in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin; in combination with neoadjuvant chemotherapy followed by adjuvant Herzuma, for locally advanced (including inflammatory) breast cancer or tumors > 2 cm in diameter.
Advanced Gastric Cancer: Herzuma in combination with capecitabine or intravenous 5-fluorouracil and a platinum agent is indicated for the treatment of patients with HER2-positive advanced adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anticancer treatment for their metastatic disease.